TABLE 1.
Baseline characteristics of autoimmune pancreatitis (AIP) type 2 patients in relation to inflammatory bowel diseases (IBD)
| Patients | Total | IBD | |
|---|---|---|---|
| n = 35 | YES (n = 29, 83%) | NO (n = 6, 17%) | |
| Female, n (%) | 18 (51.4) | 14 (48.3) | 4 (66.7%) |
| Age at AIP diagnosis (median, IQR) | 41, 26 | 38.0, 24.0 | 60.0, 35.0 |
| Follow‐up (months)* (median, IQR) | 54, 46.5 | 54.0, 47.0 | 61.5, 77.0 |
| Definite AIP 2, n (%) | 22 (62.9) | 16 (55.2) | 6 (100.0) |
| Alcohol consumption >5 U | 1 (2.9) | 1 (3.6) | 0 |
| Smoker | |||
| Never | 18 (51.4) | 17 (58.6) | 1 (16.7) |
| Former | 14 (40.0) | 11 (37.9) | 3 (50.0) |
| Active | 3 (8.6) | 1 (3.4) | 2 (33.3) |
| Diagnosis by histology, n (%) | 8 (22.9) | 3 (10.3) | 5 (83.3) |
| AIP symptoms at diagnosis, n (%) | |||
| Abdominal pain | 30 (85.7) | 27 (93.1) | 3 (50.0) |
| Weight loss | 7 (20.0) | 6 (20.7) | 1 (16.7) |
| Acute pancreatitis | 16 (45.7) | 15 (51.7) | 1 (16.7) |
| Jaundice | 4 (11.4) | 2 (6.9) | 2 (33.3) |
| New onset diabetes | 2 (5.7) | 1 (3.4) | 1 (16.7) |
| Incidental finding | 5 (14.3) | 3 (10.3) | 2 (33.3) |
| PEI, n (%) | |||
| At diagnosis | 11 (31.4) | 10 (34.5) | 1 (16.7) |
| FE‐1 (μg/g, median, IQR) | 225.3 | 220.2 | 500.3 |
| At follow‐up* | 10 (30.3) | 8 (29.6) | 2 (33.3) |
| FE‐1 (μg/g, median, IQR)* | 260.3 | 231.3 | 292.2 |
| Diabetes mellitus, n (%) | |||
| At diagnosis | 4 (11.4) | 2 (6.9) | 2 (33.3) |
| At follow‐up* | 7 (21.2) | 5 (18.5) | 2 (33.3) |
| AIP treatment, n (%) | 31 (88.6) | 25 (86.2) | 6 (100.0) |
| Surgery | 7 (20.0) | 2 (6.9) | 5 (83.3) |
| Steroids | 26 (74.3) | 25 (86.2) | 1 (16.7) |
| Azathioprine | 8 (22.9) | 8 (27.6) | 0 |
| AIP relapse, n (%)* | 8 (24.2) | 7 (25.9) | 1 (17.7) |
| AIP maintenance treatment | 4 (12.1) | 4 (14.8) | 0 |
| Clinical remission at last contact* | 33 (100.0) | 27 (100.0) | 6 (100.0) |
| Clinical remission without systemic therapy for both IBD and AIP | 22 (66.7) | 16 (59.3) | 6 (100.0) |
| Radiological remission at last contact* | 31 (93.9) | 25 (92.6) | 6 (100%) |
Note: (normal >200 μg/g; measured up to 800 μg/g). For variables with *, n = 33.
Abbreviations: AIP, autoimmune pancreatitis; CD, Crohn's disease; DM, diabetes mellitus; FE‐1, fecal elastase‐1; IBD‐inflammatory bowel disease; IQR‐interquartile range; PEI‐pancreatic exocrine insufficiency; UC‐ulcerative colitis.